EP0605024A2 - Verwendung von gereinigten Oberflächenmodifiziermitteln zur Vermeidung der Aggregation von Teilchen während der Sterilisation - Google Patents

Verwendung von gereinigten Oberflächenmodifiziermitteln zur Vermeidung der Aggregation von Teilchen während der Sterilisation Download PDF

Info

Publication number
EP0605024A2
EP0605024A2 EP93203089A EP93203089A EP0605024A2 EP 0605024 A2 EP0605024 A2 EP 0605024A2 EP 93203089 A EP93203089 A EP 93203089A EP 93203089 A EP93203089 A EP 93203089A EP 0605024 A2 EP0605024 A2 EP 0605024A2
Authority
EP
European Patent Office
Prior art keywords
cloud point
modifier
nanoparticles
surface modifier
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93203089A
Other languages
English (en)
French (fr)
Other versions
EP0605024A3 (de
Inventor
Kenneth R. C/O Sterling Winthrop Inc. Hollister
David L. C/O Sterling Winthrop Inc. Ladd
Gregory L. C/O Sterling Winthrop Inc. Mcintire
George C. C/O Sterling Winthrop Inc. Na
Natarajan C/O Sterling Winthrop Inc. Rajagopalan
Barbara O-Ching C/O Sterling Winthrop Inc. Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanosystems LLC
Original Assignee
Eastman Kodak Co
Nanosystems LLC
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastman Kodak Co, Nanosystems LLC, Sterling Winthrop Inc filed Critical Eastman Kodak Co
Publication of EP0605024A2 publication Critical patent/EP0605024A2/de
Publication of EP0605024A3 publication Critical patent/EP0605024A3/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476—Particles, beads, capsules, spheres
    • A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/049—Surface-modified nanoparticles, e.g. immune-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • This invention relates to therapeutic and diagnostic compositions with a modified cloud point, and to a method for the preparation thereof.
  • Nanoparticles described in U.S. Patent No. 5,145,684, are particles consisting of a poorly soluble therapeutic or diagnostic agent onto which are adsorbed a non-crosslinked surface modifier, and which have an average particle size of less than about 400 nanometers (nm).
  • the aggregation of nanoparticles upon heating is directly related to the precipitation and/or phase separation of the surface modifier (surfactant) at temperatures above the cloud point of the surfactant where the bound surfactant molecules are likely to dissociate from the nanoparticles and precipitate and/or phase separate, leaving the nanoparticles unprotected.
  • the unprotected nanoparticles can then aggregate into clusters of particles.
  • the surfactant redissolves into the solution, which then coats the aggregated particles and prevents them from dissociating into smaller ones.
  • This invention is directed to novel compositions that allow autoclaving of nanoparticles with reduced or no particle size growth. These compositions provide for a modification of the surfactant adsorbed onto nanoparticles such that the nanoparticles do not agglomerate during autoclaving. This invention is also directed to a method of making such compositions.
  • composition comprising nanoparticles having a purified polymeric surfactant as a surface modifier adsorbed on the surface thereof and a cloud point modifier associated therewith, which cloud point modifier is present in an amount sufficient to increase the cloud point of the surface modifier.
  • the cloud point of the surface modifier is increased above the temperature for sterilization, such as autoclaving, of the nanoparticles to prevent agglomeration.
  • the invention provides a method of making nanoparticles having a purified polymeric surfactant as a surface modifier adsorbed on the surface and a cloud point modifier associated therewith, said method comprising contacting said nanoparticles with the cloud point modifier for a time and under conditions sufficient to increase the cloud point of the surface modifier.
  • Figures 1-3 are particle size distributions of ethyl 3,5-diacetamido-2,4,6 triiodobenzoate (EEDA) particles containing T-908 surface modifier and PEG-400 cloud point modifier before and after autoclaving at 88%, 92% and 99% purity of T-908 respectively.
  • EEDA ethyl 3,5-diacetamido-2,4,6 triiodobenzoate
  • Figure 4 is a particle size distribution of EEDA particles containing T-908 surface modifier at 88%, 92% and 99% purity, and PEG-400 cloud point modifier after autoclaving at 121°C for 20 minutes.
  • Figure 5 is a particle size distribution of EEDA articles containing T-908 surface modifier at 88%, 92% and 99% purity, and PEG-400 cloud point modifier after autoclaving at 110°C for 90 minutes.
  • Figure 6 is a particle size distribution of EEDA particles containing T908 surface modifier at 88%, 92% and 99% purity and PEG-400 cloud point modifier before autoclaving.
  • the nanoparticles useful in the practice of this invention include a surface modifier.
  • Surface modifiers useful herein physically adhere to the surface of the diagnostic or therapeutic agent in nanoparticle form, but do not chemically react with the agent or themselves. Individually adsorbed molecules of the surface modifier are essentially free of intermolecular crosslinkages.
  • a surface modifier useful in the present invention is a purified polymeric surfactant.
  • a polymeric surfactant is a surfactant composed of 2 or more repeating monomeric units.
  • Exemplary polymeric surfactants are Tetronic-908 (T-908) and Tetronic-1508 (T-1508), which are members of a family of polyalkyleneoxide substituted ethylenediamine surfactants having the following idealized structure: They differ in that T-908 has a nominal average molecular weight of approximately 25,000 whereas T-1508 has a nominal average molecular weight of approximately 30,000.
  • Another exemplary polymeric surfactant which has been purified is tyloxapol.
  • a purified polymeric surfactant is a polymeric surfactant that is substantially free of polymeric impurities according to the method of the present invention. This method involves the use of extensive aqueous diafiltration, as discussed in more detail elsewhere herein, extraction with nonaqueous solvents, or treatment with hydrophobic resins, ion exchange resins, and the like.
  • substantially free of polymeric impurities means that such impurities are present in the purified polymeric surfactant useful in the present invention in an amount of less than about 15% Preferably, such impurities are present in an amount of less than about 10%, and more preferably in an amount of less than about 1%.
  • the amount of polymeric impurities in the initial sample of polymeric surfactant may be reduced by a factor of about 50%.
  • such reduction in the level of polymeric impurities is by a factor of about 90%, and more preferably by a factor of about 95%.
  • the polymeric surfactants are commercially available and/or can be prepared by techniques known in the art.
  • nanoparticles useful in the practice of this invention can be prepared according to the methods disclosed in U.S. Patent No. 5,145,684. Briefly, nanoparticles are prepared by dispersing a poorly soluble therapeutic or diagnostic agent in a liquid dispersion medium and wet-grinding the agent in the presence of grinding media to reduce the particle size of the contrast agent to an effective average particle size of less than about 400 nm. The particles can be reduced in size in the presence of a surface modifier, e.g. during the wet grinding process.
  • a general procedure for preparing the particles useful in the practice of this invention follows.
  • the therapeutic or diagnostic agent selected is obtained commercially and/or prepared by techniques known in the art as described above, in a conventional coarse form. It is preferred, but not essential, that the particle size of the coarse therapeutic or diagnostic substance selected be less than about 100 ⁇ m as determined by sieve analysis. If the coarse particle size of that agent is greater than about 100 ⁇ m, then it is preferred that the coarse particles of the therapeutic or diagnostic agent be reduced in size to less than 100 ⁇ m using a conventional milling method such as airjet or fragmentation milling.
  • the coarse therapeutic or diagnostic agent selected can then be added to a liquid medium in which it is essentially insoluble to form a premix.
  • concentration of the therapeutic or diagnostic agent in the liquid medium can vary from about 0.1-60%, and preferably is from 5-30% (w/w). It is preferred, but not essential, that the surface modifier be present in the premix.
  • concentration of the surface modifier can vary from about 0.1 to 90%, and preferably is 1-75%, more preferably 10-60% and most preferably 10-30% by weight based on the total combined weight of the drug substance and surface modifier.
  • the apparent viscosity of the premix suspension is preferably less than about 1000 centipoise.
  • the premix can be used directly by wet grinding to reduce the average particle size in the dispersion to less than 400 nm. It is preferred that the premix be used directly when a ball mill is used for attrition.
  • the therapeutic or diagnostic agent and, optionally, the surface modifier can be dispersed in the liquid medium using suitable agitation, e.g. a roller mill or a Cowles type mixer, until a homogeneous dispersion is observed in which there are no large agglomerates visible to the naked eye. It is preferred that the premix be subjected to such a premilling dispersion step when a recirculating media mill is used for attrition.
  • wet grinding can take place in any suitable dispersion mill, including, for example, a ball mill, an attritor mill, a vibratory mill, and media mills such as a sand mill and a bead mill.
  • a media mill is preferred due to the relatively shorter milling time required to provide the intended result, i.e., the desired reduction in particle size.
  • the apparent viscosity of the premix preferably is from about 100 to about 1000 centipoise.
  • the apparent viscosity of the premix preferably is from about 1 up to about 100 centipoise. Such ranges tend to afford an optimal balance between efficient particle fragmentation and media erosion.
  • the grinding media for the particle size reduction step can be selected from rigid media preferably spherical or particulate in form having an average size less than about 3 mm and, more preferably, less than about 1 mm. Such media desirably can provide the particles of the invention with shorter processing times and impart less wear to the milling equipment.
  • the selection of material for the grinding media is not believed to be critical. However, preferred media have a density greater than about 3 g/cm3.
  • Zirconium oxide, such as 95% ZrO stabilized with magnesia, zirconium silicate, and glass grinding media provide particles having levels of contamination which are believed to be acceptable for the preparation of therapeutic or diagnostic compositions.
  • other media such as stainless steel, titania, alumina, and 95% ZrO stabilized with yttrium, are believed to be useful.
  • the attrition time can vary widely and depends primarily upon the particular wet grinding mill selected. For ball mills, processing times of up to five days or longer may be required. On the other hand, processing times of less than 1 day (residence times of about one minute up to several hours) have provided the desired results using a high shear media mill.
  • the particles must be reduced in size at a temperature which does not significantly degrade the therapeutic or diagnostic agent. Processing temperatures of less than about 30-40°C are ordinarily preferred. If desired, the processing equipment can be cooled with conventional cooling equipment. The method is conveniently carried out under conditions of ambient temperature and at processing pressures which are safe and effective for the milling process. For example, ambient processing pressures are typical of ball mills, attritor mills and vibratory mills. Processing pressures up to about 140 kPa (approx. 20 psi) are typical of media milling.
  • the surface modifier if not present in the premix, must be added to the dispersion after attrition in an amount as described for the premix. Thereafter, the dispersion can be mixed, e.g. by shaking vigorously.
  • the dispersion can be subjected to a sonication step, e.g. using an ultrasonic power supply.
  • the dispersion can be subjected to ultrasonic energy having a frequency of 20-80 kHz for a time of about 1 to 120 seconds.
  • the relative amount of therapeutic or diagnostic agent and surface modifier can vary widely and the optimal amount of the surface modifier can depend, for example, upon the particular therapeutic or diagnostic agent and surface modifier selected, the critical micelle concentration of the surface modifier if it forms micelles, the hydrophilic lipophilic balance (HLB) of the stabilizer, the melting point of the stabilizer, its water solubility, the surface tension of water solutions of the stabilizer, etc.
  • the surface modifier preferably is present in an amount of about 0.1-10 mg/m2 surface area of the therapeutic or diagnostic agent.
  • the surface modifier can be present in an amount of 0.1-90%, preferably 1-75%, more preferably 10-60%, and most preferably 10-30% by weight based on the total weight of the dry particle.
  • Therapeutic and diagnostic agents useful in the composition of the present invention include those disclosed in U.S. Patent No. 5,145,684 and published European specification EP-A-0 498,482.
  • a preferred diagnostic agent is the x-ray imaging agent ethyl 3,5-diacetamido-2,4,6-triiodobenzoate (EEDA), the ethyl ester of diatrizoic acid.
  • particle size refers to a mean particle size as measured by conventional particle size measuring techniques well known to those skilled in the art, such as sedimentation field flow fractionation, photon correlation spectroscopy, or disk centrifugation.
  • an effective average particle size of less than about 400 nm it is meant that at least 90% of the particles have a particle size of less than about 400 nm when measured by the above-noted techniques.
  • the effective average particle size is less than about 300 nm, and more preferably less than about 250 nm. In some embodiments of the invention, an effective average particle size of less than about 200 nm has been achieved.
  • the effective average particle size it is preferred that at least 95% and, more preferably, at least 99% of the particles have a particle size less than the effective average, e.g. 400 nm. In particularly preferred embodiments, essentially all of the particles have a size less than 400 nm. In some embodiments, essentially all of the particles have a size less than 250 nm.
  • a method for the preparation of a nanoparticle composition according to this invention includes the steps of introducing a therapeutic or diagnostic agent, a liquid medium, grinding media, and optionally, a surface modifier into a grinding vessel; wet grinding to reduce the particle size of the therapeutic or diagnostic agent to less than about 400 nm; and separating the particles and optionally the liquid medium from the grinding vessel and grinding media, for example, by suction, filtration or evaporation. If the surface modifier is not present during wet grinding, it can be admixed with the particles thereafter.
  • the liquid medium most often water, can serve as the pharmaceutically acceptable carrier.
  • the method preferably is carried out under aseptic conditions. Thereafter, the nanoparticle composition preferably is subjected to a sterilization process.
  • sterile filtration very often will not provide adequate sterilization for nanoparticles. Therefore, other methods of sterilization are required. For example, steam or moist heat sterilization at temperatures of about 121°C for a time period of about 15 minutes can be used. At altitudes near sea level, such conditions are attained by using steam at a pressure of about 100 kPa (approx. 15 psi) in excess of atmospheric pressure.
  • Dry heat sterilization may also be performed, although the temperatures used for dry heat sterilization are typically 160°C for time periods of 1 to 2 hours.
  • the cloud point is the temperature at which the surface modifier (surfactant) precipitates out of solution as described above.
  • cloud point modifier is meant a compound which influences the cloud point of surface modifiers.
  • the cloud point modifiers useful in the present invention raise the cloud point of the surface modifiers adsorbed onto nanoparticles. In this way, the surface modifiers do not dissociate from the surface of the nanoparticles at temperatures used in autoclaving. Therefore, nanoparticles thus modified do not agglomerate during the sterilization process, and thus retain their effective average particle sizes of less than about 400 nm after sterilization.
  • cloud point modifiers examples include nonionic compounds such as polyethylene glycols, e.g. PEG 400, available from J.T. Baker Chemical Co., propylene glycol, cyclodextrin, and ethanol; anionic surfactants such as sodium dodecylsulfate and dioctylsulfosuccinate; cationic surfactants such as cetrimide, fatty acids such as caprylic acid and capryonic acid; and charged phospholipids such as dimyristoyl phosphatidyl glycerol, cardiolipin and dimyristoylphosphatidylserine.
  • a preferred cloud point modifier is polyethylene glycol.
  • the cloud point modifier is present in the compositions of the present invention in an amount sufficient to raise the cloud point of the purified polymeric surfactant.
  • a preferred amount of cloud point modifier is 0.01% to 20% (w/v).
  • a more preferred amount of cloud point modifier is 0.05% to 10% (w/v).
  • This invention further discloses a method of making nanoparticles having a purified polymeric surfactant adsorbed on the surface and a cloud point modifier associated therewith.
  • This method involves the preparation of therapeutic or diagnostic nanoparticles, as discussed elsewhere herein, and contacting those nanoparticles with a cloud point modifier. Contacting may be by admixing a suspension of nanoparticles with a solution of cloud point modifier, followed by sterilization at a temperature and for a time sufficient to effect sterilization of the nanoparticle suspension.
  • a 2% solution of T-908 of 88% purity as determined by size exclusion HPLC (SEC-HPLC) with refractive index detection in H2O was prepared for the following diafiltration experiments: (1) Approximately 50 ml 2% T-908 solution was placed in an Amicon 50 ml stirred cell with a YM-5 membrane and diafiltered against H2O. Diafiltrate fractions were collected: Fraction Amount LDD-988-128-1-A 43 ml 1-B 44 ml 1-C 17 ml 1-D 41 ml 145 ml Retentate was denoted as LDD-988-128-1 (approximately 50 ml), 88% pure by SEC-HPLC.
  • Diafiltration of this retentate against H2O was continued: initially it was ultrafiltered down to approximately 20 ml, then diafiltered until a total of approximately 150 ml of ultrafiltrate plus diafiltrate was collected as LDD-988-128-2F; the retentate was denoted as LDD-988-128-2R (approximately 20 ml), 97% pure by SEC-HPLC.
  • T-908 2% solution 330 ml was placed in an Amicon 400 ml stirred cell with a YM-10 membrane. This was then ultrafiltered down to approximately 130 ml, then diafiltered against H2O until approximately 1500 ml of ultrafiltrate plus diafiltrate was collected as LDD-988-129F; the retentate was denoted as LDD-988-129R, 96% pure by SEC-HPLC.
  • LDD-988-129F was concentrated in a stirred cell with a YM-3 membrane, then vacuum dried to yield 0.488 g of a white solid, denoted LDD-988-129X.
  • LDD-988-129X was determined to contain 74% low molecular weight (MW) impurity(s) and 26% high MW components by SEC-HPLC. Analysis of the NMR spectrum of this material has determined that it contains three olefinic compounds:
  • a 5% solution of T-908 (lot WPMM-562B, 87% pure by SEC-HPLC) was prepared by dissolving 50.0 g T-908 in 950 ml H2O. 320 ml of the 5% T-908 solution was placed in an Amicon 400 ml stirred cell with a YM-10 membrane and diafiltered against H2O. The diafiltration was stopped after 5760 ml (18 volumes) of diafiltrate was collected. The retentate (305 ml) was filtered (0.2 ⁇ m, nylon) giving LDD-988-150, 97% pure by SEC-HPLC. 100 ml of this solution was lyophilized to yield 4.55 g of a white solid denoted LDD-988-150A.
  • T-908 solution 350 ml was placed in Amicon 400 ml stirred cell with a YM-10 membrane and diafiltered against H2O until 8175 ml of diafiltrate was collected.
  • the diafiltrate was ultra-filtered down to approximately 250 ml, filtered and lyophilized to yield 15.27 g of white solid denoted LDD-988-151, 95% pure by SEC-HPLC.
  • a sample of commercial T-908 Surfactant (BASF lot WPMM-562B) was extensively diafiltered under pressure using an Osmonics 52X-OPS-S2 spiral wound diafiltration membrane.
  • the polymeric impurity level determined by size exclusion HPLC, was reduced from an initial value of 12.7% to 2.4% after 10 turnovers of diafiltration, and subsequently to undetectable levels after 40 turnovers of diafiltration.
  • the purified surfactants were employed in the preparation of nanoparticulate dispersions of x-ray contrast agent and the cloud point modifier polyethylene glycol according to the methods of the present invention and provided stability against aggregration under the desired autoclaving conditions (121°C for 20 min) which was not achieved without this purification.
  • Table 1 Sample Lot No. Purity of T-908 Particle Size (nm) Initial A* B** 111200 88% 265 435 349 GLP Tox 92% 242 326 291 030600 99% 264 267 288 * Autoclaved for 121°C for 20 minutes. **Autoclaved for 110°C for 90 minutes.
  • T-1508 (67.9% pure, as received measured by refractive index SEC-HPLC) was diafiltered using a polysulfone membrane (Osmonics 192T-HN02, 15000 to 25000 MW cutoff, available from Osmonics, Inc.) until a purity of 92% was attained.
  • the purified T-1508 stabilized nanoparticles to heat sterilization at a much smaller particle size than the crude T-1508.

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
EP93203089A 1992-12-16 1993-11-04 Verwendung von gereinigten Oberflächenmodifiziermitteln zur Vermeidung der Aggregation von Teilchen während der Sterilisation. Withdrawn EP0605024A3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US991639 1992-12-16
US07/991,639 US5352459A (en) 1992-12-16 1992-12-16 Use of purified surface modifiers to prevent particle aggregation during sterilization

Publications (2)

Publication Number Publication Date
EP0605024A2 true EP0605024A2 (de) 1994-07-06
EP0605024A3 EP0605024A3 (de) 1995-04-12

Family

ID=25537416

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93203089A Withdrawn EP0605024A3 (de) 1992-12-16 1993-11-04 Verwendung von gereinigten Oberflächenmodifiziermitteln zur Vermeidung der Aggregation von Teilchen während der Sterilisation.

Country Status (17)

Country Link
US (1) US5352459A (de)
EP (1) EP0605024A3 (de)
JP (1) JPH06211647A (de)
KR (1) KR940013541A (de)
AU (1) AU663010B2 (de)
CA (1) CA2102356A1 (de)
CZ (1) CZ261693A3 (de)
FI (1) FI935306A (de)
HU (1) HUT65783A (de)
IL (1) IL107518A0 (de)
MY (1) MY110452A (de)
NO (1) NO934271L (de)
NZ (1) NZ250116A (de)
PH (1) PH30282A (de)
RU (1) RU2114612C1 (de)
SK (1) SK141693A3 (de)
TW (1) TW438606B (de)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600532A2 (de) * 1992-12-04 1994-06-08 NanoSystems L.L.C. Anwendung von ionischen Trübungspunktmodifizierungsmittel zum Verhindern von Partikelaggregation während der Sterilisation
EP0601618A2 (de) * 1992-12-11 1994-06-15 NanoSystems L.L.C. Anwendung von geladenen Phospholipiden zur Verringerung von Nanopartikelaggregation
EP0601619A2 (de) * 1992-12-04 1994-06-15 NanoSystems L.L.C. Anwendung von ionischen Trübungspunkte-Modifizierungsmitteln für Verringerung von Nanopartikel-Aggregration während der Sterilization
EP0602700A2 (de) * 1992-12-17 1994-06-22 NanoSystems L.L.C. Nanopartikeln enthaltende Röntgenkontrastmittel mit hochmolekularen Tensiden
WO1996020734A2 (en) * 1994-12-30 1996-07-11 Nanosystems, L.L.C. Oral gastrointestinal x-ray contrast agents in combination with pharmaceutically acceptable clays and surfactants
WO1997030736A2 (en) * 1996-02-20 1997-08-28 Nycomed Imaging A/S Contrast medium
WO1998041239A1 (en) * 1997-03-14 1998-09-24 Nycomed Imaging As Compositions comprising flexible particles, non-ionic surfactant and non-ionic cloud-point modifier
WO1998048847A1 (en) * 1997-04-25 1998-11-05 Nycomed Imaging As Nanoparticle composition containing iodinated x-ray contrast agent as stabilizer for thermal sterilization
WO1998057735A1 (en) * 1997-06-19 1998-12-23 Nycomed Imaging As Surfactant compositions
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
WO2004105809A1 (en) * 2003-05-22 2004-12-09 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US6835396B2 (en) 2001-09-26 2004-12-28 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion lyophilization
WO2009032246A2 (en) * 2007-09-03 2009-03-12 Nanotherapeutics, Inc. Particulate compositions for delivery of poorly soluble drugs
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US8119163B2 (en) 1998-11-02 2012-02-21 Alkermes Pharma Ireland Limited Nanoparticulate and controlled release compositions comprising cefditoren
WO2014001424A1 (en) * 2012-06-29 2014-01-03 General Electric Company Heat stable nanoparticle preparations and associated methods thereof
US8722091B2 (en) 2001-09-26 2014-05-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion lyophilization
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525559A (en) * 1993-02-13 1996-06-11 Tioxide Specialties Limited Preparation of mixed powders
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ATE259220T1 (de) 1998-05-29 2004-02-15 Skyepharma Canada Inc Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
ID29270A (id) 1998-11-20 2001-08-16 Rtp Pharma Inc Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
AU2041101A (en) * 1999-12-08 2001-06-18 Pharmacia Corporation Eplerenone crystalline form
JP2003523954A (ja) * 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−２阻害剤組成物
AR035642A1 (es) 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
JP2004518642A (ja) * 2000-12-06 2004-06-24 ファルマシア・コーポレーション ラボラトリースケールの微粉砕化プロセス
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
DK1429731T3 (da) * 2001-09-19 2007-05-14 Elan Pharma Int Ltd Nanopartikelformuleringer indeholdende insulin
WO2003026662A1 (en) * 2001-09-25 2003-04-03 Pharmacia Corporation Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole
WO2003030872A2 (en) * 2001-10-12 2003-04-17 Elan Pharma International Ltd. Compositions having a combination of particles for immediate release and for controlled release
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
JP2005519657A (ja) * 2001-11-07 2005-07-07 インコール ファーマシューティカル カンパニー ナノ微粒子造影剤を用いた血管撮像の方法
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
ATE464880T1 (de) 2002-02-04 2010-05-15 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
AU2003222027A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
AU2003224808A1 (en) * 2002-03-28 2003-10-13 Imcor Pharmaceutical Company Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
AU2003230885A1 (en) 2002-04-12 2003-10-27 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
WO2003094894A1 (en) * 2002-05-06 2003-11-20 Elan Pharma International Ltd. Nanoparticulate nystatin formulations
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
CA2488498A1 (en) * 2002-06-10 2003-12-18 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
US7713551B2 (en) * 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
ES2365012T3 (es) * 2002-11-12 2011-09-20 Elan Pharma International Limited Formas farmacéuticas sólidas de desintegración rápida que no son friables y que comprenden pululano.
AU2003297151A1 (en) * 2002-12-17 2004-07-22 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
JP4469846B2 (ja) * 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド ナノ粒子状トピラメート製剤
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
CA2534924A1 (en) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
WO2005044234A2 (en) * 2003-11-05 2005-05-19 Elan Pharma International Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
US20060159766A1 (en) * 2004-12-15 2006-07-20 Elan Pharma International Limited Nanoparticulate tacrolimus formulations
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
WO2006074218A2 (en) * 2005-01-06 2006-07-13 Elan Pharma International Ltd. Nanoparticulate candesartan formulations
EP1853234A2 (de) 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol und injizierbare formulierungen aus benzodiazepin in form von nanoteilchen
WO2006099121A2 (en) * 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
EP1863450A1 (de) * 2005-03-16 2007-12-12 Elan Pharma International Limited Nanoteilchenförmige leukotrien-rezeptor-antagonisten/kortikosteroid-formulierungen
BRPI0606280A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
KR20070121786A (ko) * 2005-03-23 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 코르티코스테로이드 및 항히스타민 제제
MX2007012762A (es) * 2005-04-12 2008-01-14 Elan Pharma Int Ltd Composiciones de material nanoparticulado y de liberacion controlada que comprende ciclosporina.
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
CA2604735A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
EP1888037A2 (de) * 2005-05-10 2008-02-20 Elan Pharma International Limited Clopidogrel-nanopartikelformulierungen
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
CA2610480A1 (en) * 2005-06-03 2007-05-10 Scott Jenkins Nanoparticulate acetaminophen formulations
US20070042049A1 (en) * 2005-06-03 2007-02-22 Elan Pharma International, Limited Nanoparticulate benidipine compositions
ATE459341T1 (de) * 2005-06-03 2010-03-15 Elan Pharma Int Ltd Nanoteilchenförmige imatinib-mesylat- formulierungen
WO2008073068A1 (en) 2005-06-08 2008-06-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cefditoren
US20070059371A1 (en) * 2005-06-09 2007-03-15 Elan Pharma International, Limited Nanoparticulate ebastine formulations
US20070003615A1 (en) * 2005-06-13 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
EP1931340A2 (de) * 2005-06-15 2008-06-18 Elan Pharma International Limited Nanopartikuläre azelnidipin-formulierungen
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
EP1933814A2 (de) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoteilchenförmige aripiprazol-formulierungen
EP1959966B1 (de) * 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolon-formulierungen und verfahren zu ihrer herstellung und verwendung
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
EP2101735A2 (de) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoteilchenförmige formulierungen und verfahren zur herstellung und verwendung
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
WO2008149192A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (de) 2007-12-06 2013-10-09 Bend Res Inc Nanoteilchen mit einem nicht-ionisierbaren polymer und einem amin-funktionalisierten methacrylat-copolymer
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
MX2010009848A (es) * 2008-03-21 2010-09-30 Elan Pharma Int Ltd Composiciones para el suministro especifico en sitio de imatinib y metodos de uso.
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
US7828996B1 (en) * 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
HUE032426T2 (en) 2009-05-27 2017-09-28 Alkermes Pharma Ireland Ltd Inhibition of flake aggregation in nanoparticulate meloxicam formulations
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
JP6166721B2 (ja) 2011-07-22 2017-07-19 ケモセントリックス， インコーポレイテッド ４−ｔｅｒｔ−ブチル−Ｎ−［４−クロロ−２−（１−オキシ−ピリジン−４−カルボニル）−フェニル］−ベンゼンスルホンアミドのナトリウム塩の多形
EP2748146B1 (de) 2011-07-22 2017-03-08 ChemoCentryx, Inc. Kristalline form des natriumsalzes von 4-tert-butyl -n-[4-chloro-2-(1-oxy-pyridin-4-carbonyl)-phenyl]-benzolsulfonamid
EP2751094B1 (de) 2011-09-01 2018-06-20 Glaxo Group Limited Neue kristallform
CN103376650B (zh) * 2012-04-25 2016-03-02 东京应化工业株式会社 遮光层形成用感光性基材组合物的制造方法
EP2919788A4 (de) 2012-11-14 2016-05-25 Univ Johns Hopkins Verfahren und zusammensetzungen zur behandlung von schizophrenie
KR102493854B1 (ko) 2014-06-25 2023-01-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 (s)-6-((1-아세틸피페리딘-4-일)아미노)-n-(3-(3,4-디히드로이소퀴놀린-2(1h)-일)-2-히드록시프로필)피리미딘-4-카르복스아미드의 결정질 염
EP3191480A1 (de) 2014-09-08 2017-07-19 GlaxoSmithKline Intellectual Property Development Limited Kristalline formen vo 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorphenyl)-n-(5-(1,1,1-trifluor-2-methylpropan-2-yl)isoxazol-3-yl)acetamid
CN107709344B (zh) 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
CA3001722A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
AU2017311412B2 (en) 2016-08-11 2023-05-18 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
JP6784553B2 (ja) * 2016-09-20 2020-11-11 第一工業製薬株式会社 セルロースナノファイバー濃縮物の製造方法
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
CA3158280A1 (en) 2019-12-06 2021-06-10 Alex Aimetti Ganaxolone for use in treating tuberous sclerosis complex
EP4178540A1 (de) * 2020-07-09 2023-05-17 JANSSEN Pharmaceutica NV Formulierungen mit langzeitwirkung

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012523A1 (de) * 1978-11-20 1980-06-25 American Home Products Corporation Therapeutische Zusammensetzungen mit gesteigerter Bioverfügbarkeit und Verfahren zu deren Herstellung
WO1990015593A1 (en) * 1989-06-21 1990-12-27 Ytkemiska Institutet A process for the preparation of drug particles
EP0498482A2 (de) * 1991-01-25 1992-08-12 NanoSystems L.L.C. Röntgenkontrastmitteln zur Anwendung in medizinischer Bilderzeugung
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
EP0601619A2 (de) * 1992-12-04 1994-06-15 NanoSystems L.L.C. Anwendung von ionischen Trübungspunkte-Modifizierungsmitteln für Verringerung von Nanopartikel-Aggregration während der Sterilization
EP0601618A2 (de) * 1992-12-11 1994-06-15 NanoSystems L.L.C. Anwendung von geladenen Phospholipiden zur Verringerung von Nanopartikelaggregation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012523A1 (de) * 1978-11-20 1980-06-25 American Home Products Corporation Therapeutische Zusammensetzungen mit gesteigerter Bioverfügbarkeit und Verfahren zu deren Herstellung
WO1990015593A1 (en) * 1989-06-21 1990-12-27 Ytkemiska Institutet A process for the preparation of drug particles
EP0498482A2 (de) * 1991-01-25 1992-08-12 NanoSystems L.L.C. Röntgenkontrastmitteln zur Anwendung in medizinischer Bilderzeugung
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
EP0601619A2 (de) * 1992-12-04 1994-06-15 NanoSystems L.L.C. Anwendung von ionischen Trübungspunkte-Modifizierungsmitteln für Verringerung von Nanopartikel-Aggregration während der Sterilization
EP0601618A2 (de) * 1992-12-11 1994-06-15 NanoSystems L.L.C. Anwendung von geladenen Phospholipiden zur Verringerung von Nanopartikelaggregation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MICROENCAPSULATION, vol.9, no.1, March 1992, LONDON, GB pages 19 - 28 S. D. TR\STER ET AL 'Influence of the surface properties of low contact angle surfactants on the body distribution of 14C-poly(methyl methacrylate) nanoparticles' *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0601619A3 (en) * 1992-12-04 1995-11-02 Sterling Winthrop Inc Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization.
EP0601619A2 (de) * 1992-12-04 1994-06-15 NanoSystems L.L.C. Anwendung von ionischen Trübungspunkte-Modifizierungsmitteln für Verringerung von Nanopartikel-Aggregration während der Sterilization
EP0600532A2 (de) * 1992-12-04 1994-06-08 NanoSystems L.L.C. Anwendung von ionischen Trübungspunktmodifizierungsmittel zum Verhindern von Partikelaggregation während der Sterilisation
EP0600532A3 (de) * 1992-12-04 1995-02-22 Sterling Winthrop Inc Anwendung von ionischen Trübungspunktmodifizierungsmittel zum Verhindern von Partikelaggregation während der Sterilisation.
EP0601618A2 (de) * 1992-12-11 1994-06-15 NanoSystems L.L.C. Anwendung von geladenen Phospholipiden zur Verringerung von Nanopartikelaggregation
EP0601618A3 (en) * 1992-12-11 1995-11-02 Sterling Winthrop Inc Use of charged phospholipids for decreasing nanoparticulate aggregation.
EP0602700A2 (de) * 1992-12-17 1994-06-22 NanoSystems L.L.C. Nanopartikeln enthaltende Röntgenkontrastmittel mit hochmolekularen Tensiden
EP0602700A3 (de) * 1992-12-17 1994-12-21 Sterling Winthrop Inc Nanopartikeln enthaltende Röntgenkontrastmittel mit hochmolekularen Tensiden.
WO1996020734A2 (en) * 1994-12-30 1996-07-11 Nanosystems, L.L.C. Oral gastrointestinal x-ray contrast agents in combination with pharmaceutically acceptable clays and surfactants
WO1996020734A3 (en) * 1994-12-30 1996-10-10 Eastman Kodak Co Oral gastrointestinal x-ray contrast agents in combination with pharmaceutically acceptable clays and surfactants
WO1997030736A2 (en) * 1996-02-20 1997-08-28 Nycomed Imaging A/S Contrast medium
WO1997030736A3 (en) * 1996-02-20 1997-12-18 Nycomed Imaging As Contrast medium
WO1998041239A1 (en) * 1997-03-14 1998-09-24 Nycomed Imaging As Compositions comprising flexible particles, non-ionic surfactant and non-ionic cloud-point modifier
WO1998048847A1 (en) * 1997-04-25 1998-11-05 Nycomed Imaging As Nanoparticle composition containing iodinated x-ray contrast agent as stabilizer for thermal sterilization
WO1998057735A1 (en) * 1997-06-19 1998-12-23 Nycomed Imaging As Surfactant compositions
US8119163B2 (en) 1998-11-02 2012-02-21 Alkermes Pharma Ireland Limited Nanoparticulate and controlled release compositions comprising cefditoren
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US8722091B2 (en) 2001-09-26 2014-05-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion lyophilization
US6835396B2 (en) 2001-09-26 2004-12-28 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion lyophilization
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
WO2004105809A1 (en) * 2003-05-22 2004-12-09 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US7842232B2 (en) 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
WO2009032246A2 (en) * 2007-09-03 2009-03-12 Nanotherapeutics, Inc. Particulate compositions for delivery of poorly soluble drugs
US8377479B2 (en) 2007-09-03 2013-02-19 Nanotherapeutics, Inc. Compositions and methods for delivery of poorly soluble drugs
AU2008296971B2 (en) * 2007-09-03 2014-10-02 Nanoshift, Llc Particulate compositions for delivery of poorly soluble drugs
US9554996B2 (en) 2007-09-03 2017-01-31 Nanotherapeutics, Inc. Compositions and methods for delivery of poorly soluble drugs
WO2009032246A3 (en) * 2007-09-03 2009-04-23 Nanotherapeutics Inc Particulate compositions for delivery of poorly soluble drugs
WO2014001424A1 (en) * 2012-06-29 2014-01-03 General Electric Company Heat stable nanoparticle preparations and associated methods thereof
US9251937B2 (en) 2012-06-29 2016-02-02 General Electric Company Heat stable nanoparticle preparations and associated methods thereof

Also Published As

Publication number Publication date
IL107518A0 (en) 1994-02-27
SK141693A3 (en) 1994-09-07
RU2114612C1 (ru) 1998-07-10
CZ261693A3 (en) 1994-07-13
NO934271D0 (no) 1993-11-25
FI935306A (fi) 1994-06-17
CA2102356A1 (en) 1994-06-17
AU663010B2 (en) 1995-09-21
NO934271L (no) 1994-06-17
EP0605024A3 (de) 1995-04-12
TW438606B (en) 2001-06-07
JPH06211647A (ja) 1994-08-02
PH30282A (en) 1997-02-20
NZ250116A (en) 1994-09-27
US5352459A (en) 1994-10-04
KR940013541A (ko) 1994-07-15
HU9303604D0 (en) 1994-04-28
FI935306A0 (fi) 1993-11-29
HUT65783A (en) 1994-07-28
MY110452A (en) 1998-05-30
AU5046693A (en) 1994-06-30

Similar Documents

Publication Publication Date Title
EP0605024A2 (de) Verwendung von gereinigten Oberflächenmodifiziermitteln zur Vermeidung der Aggregation von Teilchen während der Sterilisation
EP0601619A2 (de) Anwendung von ionischen Trübungspunkte-Modifizierungsmitteln für Verringerung von Nanopartikel-Aggregration während der Sterilization
EP0601618A2 (de) Anwendung von geladenen Phospholipiden zur Verringerung von Nanopartikelaggregation
US5298262A (en) Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5145684A (en) Surface modified drug nanoparticles
US5622938A (en) Sugar base surfactant for nanocrystals
US5534270A (en) Method of preparing stable drug nanoparticles
EP0602700A2 (de) Nanopartikeln enthaltende Röntgenkontrastmittel mit hochmolekularen Tensiden
WO1996022766A1 (en) Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
IE83410B1 (en) Surface modified drug nanoparticles
WO1996000567A1 (en) Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanocrystal formulation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EASTMAN KODAK COMPANY

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19950915

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NANOSYSTEMS L.L.C.

17Q First examination report despatched

Effective date: 19980120

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980603